Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(BI 6727; BI-6727; BI6727)
Volasertib Chemical Structure
|Product name: Volasertib|
|Cat. No.: HY-12137|
Volasertib(BI6727) is a highly potent PLK1 inhibitor with an IC50 of 0.87 nM; shows 6- and 65-fold greater selectivity against Plk2 and Plk3.
IC50 Value: 0.87 nM
in vitro: Like BI2536, BI6727 is an ATP-competitive kinase inhibitor from the dihydropteridinone class of compounds. In addition to Plk1, BI6727 also potently inhibits two closely related kinases Plk2 and Plk3 with IC50 of 5 nM and 56 nM, respectively. BI6727 at concentrations up to 10 μM displays no inhibitory activity against a panel of >50 other kinases. BI6727 inhibits the proliferation of multiple cell lines derived from various cancer tissues, including HCT116, NCI-H460, BRO, GRANTA-519, HL-60, THP-1, and Raji cells with EC50 of 23 nM, 21 nM, 11 nM, 15 nM, 32 nM, 36 nM, and 37 nM, respectively. BI6727 treatment (100 nM) in NCI-H460 cells induces an accumulation of mitotic cells with monopolar spindles and positive staining for histone H3 phosphoserine 10, confirming that cells are arrested early in the M phase, followed by induction of apoptosis. Low nanomolar concentrations of BI6727 display potent inhibitory activity against neuroblastoma (NB) tumor-initiating cells (NB TIC) with EC50 of 21 nM, whereas only micromolar concentrations of BI6727 are cytotoxic for normal pediatric neural stem cells. BI6727 induces growth arrest of Daoy and ONS-76 medulloblastoma cells similar to BI 2536.
in vivo: Administration of BI6727 significantly inhibits the growth of multiple human carcinoma xenografts including HCT116, NCI-H460, and taxane-resistant CXB1 colon carcinoma, accompanied by an increase in the mitotic index as well as an increase in apoptosis. In in vivo studies, BI6727 shows better toxicity and pharmacokinetic profile compared to BI2536.
|M.Wt||618.81||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
DMSO ≥22mg/mL Water <1.2mg/mL Ethanol ≥122mg/mL
|1 mg||5 mg||10 mg|
|1 mM||1.6160 mL||8.0800 mL||16.1600 mL|
|5 mM||0.3232 mL||1.6160 mL||3.2320 mL|
|10 mM||0.1616 mL||0.8080 mL||1.6160 mL|
|Product Name||Sponsor Only||Condition||Start Date||End Date||Phase||Last Change Date|
|Volasertib||Boehringer Ingelheim Pharmaceuticals Inc||Acute myelogenous leukemia||30-NOV-08||30-SEP-13||Phase 2||15-NOV-13|
|Boehringer Ingelheim Corp||Acute myelogenous leukemia||31-JAN-13||30-APR-16||Phase 3||15-NOV-13|
|Boehringer Ingelheim Pharmaceuticals Inc||Ovary tumor||30-APR-10||31-MAY-13||Phase 2||15-NOV-13|
|Boehringer Ingelheim Corp||Bladder cancer||30-NOV-09||31-DEC-11||Phase 2||07-NOV-13|
|Boehringer Ingelheim Corp||Urinary tract tumor||30-NOV-09||31-DEC-11||Phase 2||07-NOV-13|
|Boehringer Ingelheim Corp||Metastatic non small cell lung cancer||31-MAR-09||30-SEP-12||Phase 2||04-NOV-13|
. Sch?ffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, Taton M, Fritsch H, Glomb P, Munzert G.A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.Eur J Cancer. 2012 Jan;48(2):179-86. Epub 2011 Nov 24.
. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, Haslinger C, Garin-Chesa P, Adolf GR.BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.Clin Cancer Res. 2009 May 1;15(9):3094-102. Epub 2009 Apr 21.
BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM, BI2536 shows 4- and 11-fold greater selectivity against Plk2 and Plk3; BI2536 also is a BRD4 inhibitor(IC50= 25 nM).
Centrinone is a selective and reversible inhibitor of polo-like kinase 4 (Plk4), a serine-threonine protein kinase that initiates centriole/centrosome assembly.
Centrinone-B is a high affinity and selective PLK4 inhibitor (Ki = 0.59 nM).
GSK461364 is a potent small molecule Polo-like kinase 1 (PLK1) inhibitor with a Ki of 2.2 nM.
GW843682X is a selective PLK1 and PLK3 inhibitor with IC50s of 2.2 nM(PLK1) and 9.1 nM(PLK3); displays > 100-fold selectivity over ~30 other kinases tested including cdk1 and cdk2.
HMN-214(IVX214) is a potent PLK1 inhibitor an average IC50 of 0.12 (mu)M.
LFM-A13 is a potent and selective inhibitor of Btk with IC50 of 17.2 uM; also inhibits PLK3 with IC50 of 7.2 uM.
MLN0905 is a small-molecule and potent inhibitor of PLK1 with IC50 of 2 nM.
NMS-1286937(NMS-P937) is an orally bioavailable, small-molecule Polo-like kinase 1 (PLK1) inhibitor(IC50=2 nM) with potential antineoplastic activity; no inhibition on PLK2 and PLK3.
The phosphoserine/phosphothreonine recognition site of the polo-box domain of polo-like kinase 1 is the binding pocket for thymoquinone and its analogue poloxime. Both small molecules displace phosphopeptides bound with the polo-box domain in a slow but noncovalent binding mode.